Actively Recruiting

Phase 3
Age: 18Years - 85Years
All Genders
ID07144852

Study to Evaluate Efficacy and Safety of Reformulated Levulan Kerastick Plus Photodynamic Therapy for Actinic Keratosis on Upper Extremities

Led by Sun Pharmaceutical Industries, Inc. · Updated on 2026-04-22

260

Participants Needed

20

Research Sites

12 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the efficacy and safety of a reformulated Levulan Kerastick solution containing aminolevulinic acid hydrochloride (ALA HCl) 20%, combined with photodynamic therapy (PDT), for treating actinic keratosis (AK) lesions on the upper extremities. This Phase 3, randomized, multi-center, evaluator-blind, vehicle-controlled study focuses on adults with 4-8 mild to moderate AK lesions on one arm. The study aims to assess complete clearance of AK lesions and other related outcomes including partial clearance, lesion count changes, recurrence, cosmetic response, and patient satisfaction. Participants will be randomly assigned to receive either the active treatment with reformulated Levulan Kerastick plus blue light PDT or a vehicle solution plus blue light PDT. Treatment involves applying the solution with occlusion and incubation followed by exposure to blue light using the BLU-U4170E device. Up to two PDT sessions may be administered depending on lesion clearance. The study includes a control group receiving the vehicle solution to compare outcomes. During the study, participants will undergo evaluations at multiple time points including weeks 4, 8, 12, 20, and 24 to assess lesion clearance, cosmetic response, and patient satisfaction. Safety monitoring includes checks for adverse events, local skin reactions, vital signs, and laboratory tests. The primary outcome, complete clearance rate, will be measured at week 12. The total study duration involves follow-up through week 24 to assess sustained effects and recurrence rates.

CONDITIONS

Brief Title

Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Upper Extremities

Who Can Participate

Age: 18Years - 85Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or non-pregnant female aged 18 to 85 years
  • 4 to 8 mild to moderate actinic keratosis lesions (Olsen grade 1 or 2) on one upper arm, each up to 1 cm in diameter and spaced at least 1 cm apart
  • Treatment area approximately 25 cm² on the extensor surface of one upper extremity
  • Good general health and able to avoid sunbathing or tanning devices
  • Willing to stop using all topical products in the treatment area within 8 hours before clinic visits
  • Women of childbearing potential must use highly effective contraception; men with such partners must use barrier methods unless surgically sterile
Not Eligible

You will not qualify if you...

  • Presence of Olsen grade 3 actinic keratosis, untreated or suspicious skin cancers, or significant skin abnormalities in the treatment area
  • Active herpes simplex infection or history of 2 or more outbreaks in the treatment area within the past year
  • History of cutaneous photosensitization, porphyria, photodermatosis, or hypersensitivity to porphyrins
  • Positive HIV test, hepatitis B surface antigen, or hepatitis C virus test
  • Immunosuppressed status or known coagulation defects
  • Use of specific topical therapies (retinoids, steroids, cryotherapy, PDT, chemical peels) on the treatment area within 2 days to 8 weeks prior to randomization
  • Recent use of certain systemic therapies (corticosteroids, immune-modulators, retinoids, cytotoxic drugs) within 6 weeks to 6 months prior to randomization
  • Recent use of phototoxic or photoallergic medications (e.g., tetracyclines, psoralenes, St. John's wort) within 8 weeks of randomization
  • Clinically significant or unstable illnesses, or history of alcohol/drug abuse in the past year
  • Pregnancy or lactation, recent or current participation in another clinical study, or other conditions deemed unsuitable by the Investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Single treatment session with follow-up assessments up to 24 weeks

Participants receive topical application of either the reformulated Levulan Kerastick or vehicle, followed by incubation with occlusion and subsequent blue light photodynamic therapy on the treatment area.

1 treatment visit and multiple follow-up visits at Weeks 4, 8, 12, 20, and 24

Trial Site Locations

Total: 20 locations

1

Medical Dermatology Specialist

Phoenix, Arizona, United States, 85006

Actively Recruiting

2

Center for Dermatology Clinical Research, Inc

Fremont, California, United States, 94538

Actively Recruiting

3

Clarity Dermatology, PLLC

Castle Rock, Colorado, United States, 80109

Actively Recruiting

4

Center for Clinical and Cosmetic Research

Aventura, Florida, United States, 33180

Actively Recruiting

5

Ziaderm Research LLC

North Miami Beach, Florida, United States, 33162

Actively Recruiting

6

Northwest Clinical Trials, Inc.

Boise, Idaho, United States, 83704

Actively Recruiting

7

Arlington Dermatology

Rolling Meadows, Illinois, United States, 60008

Actively Recruiting

8

The Indiana Clinical Trials Center, PC

Plainfield, Indiana, United States, 46168

Actively Recruiting

9

Minnesota Clinical Study Center

New Brighton, Minnesota, United States, 55112

Actively Recruiting

10

Medisearch, LLC

Saint Joseph, Missouri, United States, 64506

Actively Recruiting

11

Oregon Dermatology and Research Center

Portland, Oregon, United States, 97210

Actively Recruiting

12

Dermatology Associates of Plymouth Meeting

Plymouth Meeting, Pennsylvania, United States, 19462

Actively Recruiting

13

Palmetto Clinical Trial Services, LLC

Anderson, South Carolina, United States, 29621

Actively Recruiting

14

Palmetto Clinical Trial Services, LLC

Greenville, South Carolina, United States, 29615

Actively Recruiting

15

Dermatology Associates of Knoxville

Knoxville, Tennessee, United States, 37909

Actively Recruiting

16

Tennessee Clinical Research Center

Nashville, Tennessee, United States, 37215

Actively Recruiting

17

J&S Studies, Inc

College Station, Texas, United States, 77845

Actively Recruiting

18

Pflugerville Dermatology Clinical Research Center, Inc. d/b/a Austin Institute for Clinical Research

Pflugerville, Texas, United States, 78660

Actively Recruiting

19

Dermatology of Seattle & Bellevue

Burien, Washington, United States, 98168

Actively Recruiting

20

Premier Clinical Research

Spokane, Washington, United States, 99202

Actively Recruiting

Loading map...

Research Team

H

Head, Regulatory Affairs

How is the study designed?

Study Type

INTERVENTIONAL

Masking

TRIPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Randomized, Multi-Center, Evaluator-Blind Study of Reformula...

Actinic Keratosis

Actively Recruiting

10 locations

Acid Sphingomyelinase Inhibition to Mitigate Risks of UV Lig...

Actinic Keratosis

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here